Astrazeneca AB v Comptroller General of Patents, Designs and Trade Marks.

Core Citations

WORK EXPRESSION OF in

• Astrazeneca AB v Comptroller General of Patents, Designs and Trade Marks.

This document cites

• Neurim Pharmaceuticals (1991) Ltd v Comptroller-General of Patents.
• Novartis AG, University College London and Institute of Microbiology and Epidemiology v Comptroller-General of Patents, Designs and Trade Marks for the United Kingdom (C-207/03) and Ministre de l'Économie v Millennium Pharmaceuticals Inc. (C-252/03).
• Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products
• Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use
• Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (Codified version) (Text with EEA relevance)



See all quotations

• Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by Law, Regulation or Administrative Action relating to proprietary medicinal products
• Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products
• Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (Text with EEA relevance)Text with EEA relevance
• Rules of Procedure of the Court of Justice
• Treaty establishing the European Community